For a life sciences company, ongoing innovation, access to capital, and the ability to obtain regulatory approval are the cornerstones for success. Improving operational, financial, and risk management practices as you grow enhances your ability to attract investors, commercialize, and exit when the time is right. CohnReznick’s Life Sciences Industry specialists serve as trusted accounting, tax, and business advisors to assist you in making critical go-forward decisions.
WIDE SECTOR EXPERTISEBiotechnology, pharmaceutical services, medical devices, diagnostics, and therapeutics companies are among our client roster and speak to our experience in this industry.
SPECIALIZED KNOWLEDGEWe work with complex licensing deals, tax-sensitive financing structures, purchase price allocations and stock valuations, and provide specialized advisory services.
PROACTIVE INDUSTRY PARTICIPATIONOur professionals are actively involved with industry professional associations, trade organizations, and investor groups.
PCAOB REGISTRATIONCohnReznick is registered with the Public Company Accounting Oversight Board (PCAOB), providing audit services and advising CEOs, CFOs, and audit committees on SEC rulings and compliance with changing accounting requirements.
CAPITAL MARKETS ACCESSOur experience with the capital markets community supports both buy and sell-side M&A transactions. We can take your company through a private equity, venture capital, corporate, or IPO transaction as your auditor or by providing consulting services such as valuation, financial structuring, and the corporate governance advisory you need as you grow.
TAX PLANNING AND CREDITSOur in-depth knowledge of the applicable tax code, and experience with orphan drug and research and development tax credits, allows us to help you maximize tax advantages. This extends to transfer pricing and international tax structuring if your business has overseas operations.
LICENSING AGREEMENTSWe help structure agreements and put systems in place to ensure compliance over the duration of contracts for these essential sources of income and market exposure.
CYBERSECURITYWe identify threats and protect life sciences companies from intrusions, threat, and sabotage. Our services help you maintain the confidentiality and integrity of technology resources and data.
With companies staying private longer these days, don’t be in a big hurry for your IPO. Capital raising activities and burn rate should reflect current market conditions.
Learn more about Emerging Markets
InsightLife Sciences IPO Market Remains Consistently Strong in 2018, With Q3 No ExceptionLife sciences with biotech companies paving the way represent a significant portion of IPOs in 2018.
InsightThe Role of the Controller in a Life Sciences Company Has Transformed – Will You Be Left Behind?The life sciences sector is growing rapidly and this presents increased demands and new challenges for today’s controller.
Insight2018 May Be Banner Year for Life Sciences DealsOn the heels of the January 8-11, 2018 JP Morgan Annual Healthcare Conference, there is strong momentum among the life sciences industry for 2018. Despite the existing challenges of raising capital in the public markets, this year may be ideal and advantageous for life science companies to get financial deals done. But they need to act quickly.